XML 40 R32.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders' equity (Tables)
12 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Schedule of common stock reserved for future issuance
As of June 30, 2025 and June 30, 2024, common stock reserved for future issuance consisted of the following:

 
  
June 30,
2025
 
  
June 30,
2024
 
Common stock warrants outstanding
     20,443,496        34,271,146  
Common stock options issued and outstanding
     4,902,140        1,182,140  
Shares available for future issuance under the 2020 Plan
     3,302,397        22.397  
Shares reserved for common stock under the At the Market Offering
     8,000,000        —   
  
 
 
    
 
 
 
Total
     36,648,033        35,475,683  
  
 
 
    
 
 
 
Schedule of warrants or rights
The activity related to warrants for the fiscal years ended June 30, 2025 and 2024, is summarized as follows:

 
  
Common
Stock from
Warrants
 
  
Weighted-
average
Exercise
Price (per
share)
 
Outstanding at July 1, 2023
     2,348,039      $ 8.86  
Pre-funded
warrants issued August 11, 2023
     15,126,226      $ 0.0001  
Common warrants issued August 11, 2023
     16,002,175      $ 3.86  
Pre-funded
warrants issued April 22, 2024
     2,584,239      $ 0.0001  
Common warrants exercised
     (738,187    $ 3.86  
Series 2 warrants exercised
     (98,039    $ 1.9299  
Pre-funded
warrants exercised
     (953,307    $ 0.0001  
  
 
 
    
 
 
 
Outstanding and exercisable at June 30, 2024
     34,271,146      $ 1.8453  
  
 
 
    
 
 
 
Pre-funded
warrants issued March 25, 2025
     300,000      $ 0.0001  
Pre-funded
warrants exercised
     (2,374,583    $ 0.0001  
Series 2 warrants exercised
     (1,553,927    $ 1.9299  
Common warrants exercised
     (10,192,840    $ 3.86  
Purchase warrants expired
     (6,300    $ 178.50  
  
 
 
    
 
 
 
Outstanding and exercisable at June 30, 2025
     20,443,496      $ 0.9672  
  
 
 
    
 
 
 
Schedule of equity awards
The activity related to equity awards, which are comprised of stock options during the fiscal years ended June 30, 2025 and 2024, respectively, is summarized as follows:
 
 
  
Stock
Options
 
  
Weighted-
average
Exercise
Price
 
  
Weighted-
average
Remaining
Contractual
Term
 
  
Aggregate
Intrinsic
Value
 
Outstanding at July 1, 2023
     107,993     $ 31.88       8.96 years      $ 11,888  
Granted
     1,076,538       5.01       9.66 years     
Expired
     (2,038     501.93       —      
Forfeited
     (353     74.18       —      
  
 
 
   
 
 
   
 
 
    
 
 
 
Outstanding at June 30, 2024
     1,182,140     $ 6.58       9.51 years      $ 2,342,847  
Granted
     3,720,000       12.16       9.47 years     
Expired
     —        —        —      
Forfeited
     —        —        —      
  
 
 
   
 
 
   
 
 
    
 
 
 
Outstanding at June 30, 2025
     4,902,140     $ 10.81       9.24 years      $ 7,728,384  
Exercisable at June 30, 2025
     858,377     $ 10.68       8.86 years      $ 2,750,369  
  
 
 
   
 
 
   
 
 
    
 
 
 
Schedule of share-based compensation expense
The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions:
 
    
Fiscal Year Ended
June 30,
 
    
2025
   
2024
 
Expected volatility
     121.2     120.8
Expected term
     6 years       6 years  
Risk-free interest rate
     4.12     4.12
Expected dividend yield
     —      — 
Schedule of equity-based compensation expense
The classification of share-based compensation expense is summarized as follows:
 
(US$’000)
  
June 30,
 
 
  
2025
 
  
2024
 
Research and development
   $ 2,299      $ 239  
General and administrative
     15,127        591  
  
 
 
    
 
 
 
Total share-based compensation expense
   $ 17,426      $ 830